28135040|t|Lipid levels and risk of recurrent venous thrombosis: results from the MEGA follow-up study
28135040|a|Essentials The role of lipid levels in the risk of recurrent venous thrombosis is unclear. Lipids were assessed in patients with a first venous thrombosis (n = 2106) followed for 6.9 years. Lipids were not associated with recurrence, overall or in patients with unprovoked first events. Testing lipid levels is not useful to identify patients at an increased risk of recurrence. Background Knowledge of risk factors for recurrent venous thrombosis may guide decisions on duration of anticoagulation. The association between lipid levels and first venous thrombosis has been studied extensively. However, data on the role of lipids in the risk of recurrence are scarce. Objective To assess the association between lipid levels and recurrent venous thrombosis. Patients /Methods Patients with a first venous thrombosis from the MEGA study were included. Follow-up started at the date of end of anticoagulant treatment. Percentile categories of total / low-density lipoprotein / high-density lipoprotein cholesterol, triglycerides and apolipoproteins B and A1 were established (< 10th, 10th-25th, 25th-75th [reference], 75th-90th, > 90th percentile). Lipids were measured at least 3 months after discontinuing anticoagulation. Results Of 2106 patients followed for a median of 6.9 years, 326 developed recurrence (incidence rate, 2.7/100 patient - years; 95% confidence interval [CI], 2.5-3.1). With hazard ratios ranging from 0.88 (95% CI, 0.55-1.42) to 1.33 (95% CI, 0.86-2.04) in the highest percentile category vs. the reference, we found no association across percentile categories between recurrence and lipid levels in age- and sex -adjusted models, nor after further adjustments for body mass index, diabetes, estrogen and statin use, and duration of anticoagulation. Subgroup analyses stratified by unprovoked or provoked first events, location (deep vein thrombosis or pulmonary embolism) and sex also did not reveal an association with any of the lipid levels studied. Conclusions Testing lipid levels did not identify patients at an increased risk of recurrent venous thrombosis in this study, including those with unprovoked first events, and these should not influence decisions on duration of anticoagulation.
28135040	0	12	Lipid levels	T059	C0523744
28135040	17	21	risk	T078	C0035647
28135040	25	52	recurrent venous thrombosis	T046	C1735901
28135040	54	61	results	T169	C1274040
28135040	71	91	MEGA follow-up study	T062	C0016441
28135040	115	127	lipid levels	T059	C0523744
28135040	135	139	risk	T078	C0035647
28135040	143	170	recurrent venous thrombosis	T046	C1735901
28135040	174	181	unclear	T033	C3845108
28135040	183	189	Lipids	T109	C0023779
28135040	195	203	assessed	T052	C1516048
28135040	207	215	patients	T101	C0030705
28135040	229	246	venous thrombosis	T046	C0042487
28135040	258	266	followed	T079	C0332283
28135040	275	280	years	T079	C0439234
28135040	282	288	Lipids	T109	C0023779
28135040	298	313	associated with	T080	C0332281
28135040	314	324	recurrence	T067	C0034897
28135040	340	348	patients	T101	C0030705
28135040	371	377	events	T051	C0441471
28135040	379	399	Testing lipid levels	T059	C0523744
28135040	407	413	useful	T080	C3827682
28135040	417	425	identify	T080	C0205396
28135040	426	434	patients	T101	C0030705
28135040	441	450	increased	T081	C0205217
28135040	451	455	risk	T078	C0035647
28135040	459	469	recurrence	T067	C0034897
28135040	495	507	risk factors	T033	C0035648
28135040	512	539	recurrent venous thrombosis	T046	C1735901
28135040	563	571	duration	T079	C0449238
28135040	575	590	anticoagulation	T061	C0003281
28135040	596	607	association	T080	C0439849
28135040	616	628	lipid levels	T059	C0523744
28135040	639	656	venous thrombosis	T046	C0042487
28135040	696	700	data	T078	C1511726
28135040	716	722	lipids	T109	C0023779
28135040	730	734	risk	T078	C0035647
28135040	738	748	recurrence	T067	C0034897
28135040	774	780	assess	T052	C1516048
28135040	785	796	association	T080	C0439849
28135040	805	817	lipid levels	T059	C0523744
28135040	822	849	recurrent venous thrombosis	T046	C1735901
28135040	851	859	Patients	T101	C0030705
28135040	869	877	Patients	T101	C0030705
28135040	891	908	venous thrombosis	T046	C0042487
28135040	918	928	MEGA study	T062	C0016441
28135040	934	942	included	T169	C0332257
28135040	944	953	Follow-up	T058	C1522577
28135040	954	961	started	T080	C1272689
28135040	969	973	date	T079	C0011008
28135040	977	980	end	T082	C0444930
28135040	984	1007	anticoagulant treatment	T061	C0150457
28135040	1009	1019	Percentile	T081	C1264641
28135040	1020	1030	categories	T170	C0683312
28135040	1034	1039	total	T109	C0543421
28135040	1042	1065	low-density lipoprotein	T109,T123	C0023824
28135040	1068	1104	high-density lipoprotein cholesterol	T109,T123	C0023822
28135040	1106	1119	triglycerides	T109,T123	C0041004
28135040	1124	1141	apolipoproteins B	T116,T123	C0003593
28135040	1146	1148	A1	T116,T123	C0085201
28135040	1154	1165	established	T080	C0443211
28135040	1197	1206	reference	T081	C0034925
28135040	1227	1237	percentile	T081	C1264641
28135040	1240	1246	Lipids	T109	C0023779
28135040	1252	1260	measured	T080	C0444706
28135040	1272	1278	months	T079	C0439231
28135040	1285	1298	discontinuing	T033	C1444662
28135040	1299	1314	anticoagulation	T061	C0003281
28135040	1316	1323	Results	T169	C1274040
28135040	1332	1340	patients	T101	C0030705
28135040	1370	1375	years	T079	C0439234
28135040	1391	1401	recurrence	T067	C0034897
28135040	1403	1417	incidence rate	T081	C1708485
28135040	1427	1434	patient	T101	C0030705
28135040	1437	1442	years	T079	C0439234
28135040	1448	1467	confidence interval	T081	C0009667
28135040	1469	1471	CI	T081	C0009667
28135040	1489	1502	hazard ratios	T081	C2985465
28135040	1503	1510	ranging	T081	C1514721
28135040	1526	1528	CI	T081	C0009667
28135040	1554	1556	CI	T081	C0009667
28135040	1584	1594	percentile	T081	C1264641
28135040	1595	1603	category	T170	C0683312
28135040	1612	1621	reference	T081	C0034925
28135040	1635	1646	association	T080	C0439849
28135040	1654	1664	percentile	T081	C1264641
28135040	1665	1675	categories	T170	C0683312
28135040	1684	1694	recurrence	T067	C0034897
28135040	1699	1711	lipid levels	T059	C0523744
28135040	1715	1719	age-	T032	C0001779
28135040	1724	1727	sex	T032	C0079399
28135040	1738	1744	models	T075	C0026339
28135040	1756	1763	further	T082	C1517331
28135040	1764	1775	adjustments	T169	C0456081
28135040	1780	1795	body mass index	T201	C1305855
28135040	1797	1805	diabetes	T047	C0011847
28135040	1807	1815	estrogen	T109,T121,T125	C0014939
28135040	1820	1826	statin	T109,T121	C0360714
28135040	1827	1830	use	T169	C0457083
28135040	1836	1844	duration	T079	C0449238
28135040	1848	1863	anticoagulation	T061	C0003281
28135040	1865	1873	Subgroup	T185	C1515021
28135040	1874	1882	analyses	T062	C0936012
28135040	1883	1893	stratified	T080	C0205363
28135040	1911	1919	provoked	T080	C1444748
28135040	1926	1932	events	T051	C0441471
28135040	1934	1942	location	T082	C0450429
28135040	1944	1964	deep vein thrombosis	T047	C0149871
28135040	1968	1986	pulmonary embolism	T047	C0034065
28135040	1992	1995	sex	T032	C0079399
28135040	2009	2015	reveal	T080	C0443289
28135040	2019	2030	association	T080	C0439849
28135040	2047	2059	lipid levels	T059	C0523744
28135040	2081	2101	Testing lipid levels	T059	C0523744
28135040	2110	2118	identify	T080	C0205396
28135040	2119	2127	patients	T101	C0030705
28135040	2134	2143	increased	T081	C0205217
28135040	2144	2148	risk	T078	C0035647
28135040	2152	2179	recurrent venous thrombosis	T046	C1735901
28135040	2188	2193	study	T062	C2603343
28135040	2233	2239	events	T051	C0441471
28135040	2262	2271	influence	T077	C4054723
28135040	2285	2293	duration	T079	C0449238
28135040	2297	2312	anticoagulation	T061	C0003281